Noxopharm Subsidiary Announces Important Drug Discovery

SYDNEY, Sept. 24, 2018 /PRNewswire/ -- * New family of drug candidates inhibit the 'master switch' involved in inflammation and autoimmunity * Able to cross the blood-brain barrier and blood-nerve barriers * Opens development of treatments of inflammatory and autoimmune diseases of the bra...